Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
Holding REGN?
Track your performance easily
REGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$753.69 - $1,211.20
Previous Close$756.81
Volume1.37M
Average Volume (3M)669.75K
Market Cap
$83.17B
Enterprise Value$76.07B
Total Cash (Recent Filing)$9.80B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)18.7
Beta0.72
Next Earnings
Jan 31, 2025EPS Estimate
$11.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)40.41
Shares Outstanding109,889,531
10 Day Avg. Volume802,145
30 Day Avg. Volume669,746
Standard Deviation0.09
R-Squared0.00682
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.84
Price to Sales (P/S)6.21
Price to Cash Flow (P/CF)16.70
P/FCF Ratio20.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.49
Enterprise Value/Gross Profit6.73
Enterprise Value/Ebitda13.83
Forecast
1Y Price Target
$1,097.00Price Target Upside44.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
Regeneron News
PremiumMarket News
QQQ ETF Update, 11/21/2024 
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQ3 total revenue of $3.72B was above consensus of $3.66B, showcasing strong financial performance.
Market PotentialRegeneron's pipeline is well positioned in hot areas of oncology and cardiometabolic, potentially providing upside to shares.
Product LaunchEylea HD is anticipated to become the new standard of care for Wet Age-Related Macular Degeneration and Diabetic Macular Edema.
Bears Say
Market CompetitionThe Eylea franchise has already been facing stiff competition from Roche's Vabysmo, but a new upset came with recent news that Amgen will be launching a biosimilar version of Eylea SD soon, calling into question the trajectory of the franchise.
Product Launch ChallengesThe EYLEA HD launch and switch from 2mg EYLEA has been more challenging than expected, with meaningful acceleration not anticipated until much later, complicating the outlook for EYLEA.
Sales PerformanceEylea HD sales fell short of expectations, which could be a concern for investors as REGN faces a tougher challenge after the recent launch of the first biosimilar.
---
Ownership Overview
1.94% Insiders
33.75% Mutual Funds
19.61% Other Institutional Investors
20.32% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $753.69 and its highest was $1211.20 in the past 12 months.
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Jan 31, 2025 which is in 69 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Oct 31, 2024. The company reported $12.46 earnings per share for the quarter, beating the consensus estimate of $11.695 by $0.765.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is $11.11.
How many shares outstanding does Regeneron have?
Regeneron has 108,072,390 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $12.46 in its last earnings report, beating expectations of $11.695. Following the earnings report the stock price went down -9.167%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,097.00 (44.95% Upside)
$1,097.00 (44.95% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 109.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.48%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
16.41%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
REGN Company Deck
---
REGN Earnings Call
Q3 2024
0:00 / 0:00
---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Month Forecast
Average Price Target
$1,097.00
▲(44.95% Upside)
Technical Analysis
Best Analysts Covering REGN
1 Year
1 Year Success Rate
30/42 ratings generated profit
1 Year Average Return
+20.77%
assigned a buy rating 20 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +20.77% per trade.
---